Ventana pd l1 sp142 assay

Manufactured by Roche

Sourced in United States

The Ventana PD-L1 (SP142) assay is a qualitative immunohistochemistry assay used to detect the programmed death-ligand 1 (PD-L1) protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma and non-small cell lung cancer (NSCLC) tissue specimens. The assay utilizes the SP142 rabbit monoclonal primary antibody to identify PD-L1 protein expression in tumor cells and tumor-infiltrating immune cells.

Automatically generated - may contain errors

Lab products found in correlation

Pd l1 ihc 22c3 pharmdx, by Agilent Technologies (1 mentions) Ventana pd l1 sp263 assay, by Roche (1 mentions)

4 protocols using ventana pd l1 sp142 assay

Automated PD-L1 Immunohistochemistry Staining

Check if the same lab product or an alternative is used in the 5 most similar protocols

Freshly cut, 4 micron slides were stained using the VENTANA PD-L1 (SP142) Assay (Ventana Medical Systems, Tucson, Arizona) according to manufacturer instructions. Stainings were performed on a Ventana BenchMark Ultra immuno stainer (Ventana Medical Systems, Tucson, Arizona). Normal tonsil tissue was used as a control for each case.
Slides were scanned using the Phillips UltraFast Scanners (Philips Digital Pathology Solutions, Best, the Netherlands) to obtain high-resolution whole slide digital images.

Ben Dori S., Aizic A., Zubkov A., Tsuriel S., Sabo E, & Hershkovitz D. (2022). The risk of PD-L1 expression misclassification in triple-negative breast cancer. Breast Cancer Research and Treatment, 194(2), 297-305.

+ Open protocol

+ Expand

Standardizing PD-L1 Immunohistochemistry Assays

Check if the same lab product or an alternative is used in the 5 most similar protocols

Using the respective institutional research ethics board approval, 18 pathologists contributed eight unstained serial sections prepared from paraffin blocks of 81 lung cancer cases that they had collected through their routine clinical practice. The final cases included 39 adenocarcinomas, 26 squamous cell carcinomas, six poorly differentiated non–small cell carcinomas, and 10 small cell carcinomas (Supplementary Table 1). The cases included 21 resections, 20 core needle or bronchial biopsy samples, 18 tumor-positive lymph node excision biopsy or resection samples, and 22 cytological cell blocks.
The PD-L1 IHC 22C3 pharmDx and PD-L1 28–8 pharmDx assays were purchased from Dako (Heverlee, Belgium). The Ventana PD-L1 (SP142) assay and Ventana PD-L1 (SP263) assay were purchased from Ventana (Tucson, AZ). The 73–10 antibody was provided by EMD Serono/Merck KGaA/Pfizer through Dako/Agilent together with its staining protocol (see below).

Tsao M.S., Kerr K.M., Kockx M., Beasley M.B., Borczuk A.C., Botling J., Bubendorf L., Chirieac L., Chen G., Chou T.Y., Chung J.H., Dacic S., Lantuejoul S., Mino-Kenudson M., Moreira A.L., Nicholson A.G., Noguchi M., Pelosi G., Poleri C., Russell P.A., Sauter J., Thunnissen E., Wistuba I., Yu H., Wynes M.W., Pintilie M., Yatabe Y, & Hirsch F.R. (2018). PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 13(9), 1302-1311.

+ Open protocol

+ Expand

Tumor PD-L1 Expression Characterization

Check if the same lab product or an alternative is used in the 5 most similar protocols

Tumor tissues were collected from the participants (n = 23). Formalin-fixed paraffin-embedded tumor blocks were sliced into 3-μm thick sections. Tumor PD-L1 expression was measured using the Ventana PD-L1 (SP142) assay (Ventana Medical Systems, Tucson, AZ, USA), and PD-L1 positivity was defined as ≥5% of tumor-infiltrating immune cells via membrane staining.

Chiang P.J., Xu T., Cha T.L., Tsai Y.T., Liu S.Y., Wu S.T., Meng E., Tsao C.W., Kao C.C., Chen C.L., Sun G.H., Yu D.S., Chang S.Y, & Yang M.H. (2021). Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma. Biology, 10(7), 674.

+ Open protocol

+ Expand

Immune Profiling of Tumor Biopsies

Check if the same lab product or an alternative is used in the 5 most similar protocols

Core needle tumor biopsies were collected prior to therapy and while on treatment (range 1–4 months on treatment, median 1.5 months), and fixed in formalin, embedded in paraffin, and processed into 5 μm sections. Immunohistochemistry (IHC) for PD-L1 protein expression was performed using the Ventana PD-L1 (SP142) assay (Ventana, Tucson AZ), and scored using a cut-off of 5% tumor cell or immune cell staining and positivity according to the diagnostic label for the assay. CD8 clone C8/144B was used to evaluate CD8 positive cell staining (HistoGeneX, Antwerpen, Belgium). To calculate the change in CD8⁺ T cell infiltration, a noise floor of 0.5% was applied to the percentage of the tumor area positive for CD8 staining, and then Log₂ (the area of on-treatment CD8⁺ / pre-treatment CD8⁺) was calculated for each patient with paired biopsies. An unpooled two-tailed t-test was performed comparing the patients with DCR < 6mo and DCR ≥ 6mo to calculate the p-value. CD73 clone D7F9A was used to evaluate CD73 positive cell staining (HistoGeneX, Antwerpen, Belgium).

Fong L., Hotson A., Powderly J.D., Sznol M., Heist R.S., Choueiri T.K., George S., Hughes B.G., Hellmann M.D., Shepard D.R., Rini B.I., Kummar S., Weise A.M., Riese M.J., Markman B., Emens L.A., Mahadevan D., Luke J.J., Laport G., Brody J.D., Hernandez-Aya L., Bonomi P., Goldman J.W., Berim L., Renouf D.J., Goodwin R.A., Munneke B., Ho P.Y., Hsieh J., McCaffery I., Kwei L., Willingham S.B, & Miller R.A. (2019). Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer discovery, 10(1), 40-53.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!